Dimopoulos M A, Daliani D, Pugh W, Gershenson D, Cabanillas F, Sarris A H
Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Gynecol Oncol. 1997 Mar;64(3):446-50. doi: 10.1006/gyno.1996.4583.
Because the outcome of patients with primary ovarian non-Hodgkin's lymphoma (NHL) is controversial, we retrospectively analyzed experience with adults seen at the University of Texas M. D. Anderson Cancer Center from 1974 to 1993. Patients were included if at least one ovary was pathologically involved, and if combination chemotherapy was used that must have included doxorubicin for intermediate grade histologies. We identified 15 patients who constituted 0.5% of all untreated NHL and 1.5% of untreated ovarian neoplasms that presented to our instutition during this time. One patient refused therapy, leaving 14 assessable for response. Nine patients had intermediate-grade, 5 had high-grade, and none had low-grade NHL. One ovary was involved in 4 patients, and both in 10, in 7 of whom additional sites were involved, including supradiaphragmatic nodes in 2. Four patients had AAS I and 10 had AAS IV. Favorable (0 or 1) and unfavorable (>1) IPI scores were seen in 5 and 9 patients, respectively. The complete remission rate for all patients was 64%, and 5-year survival and FFS for all assessable patients were 57 and 46%, respectively. We conclude that the complete remission rate and FFS of patients with ovarian NHL treated with appropriate chemotherapy appear to be similar to that of patients with other nodal NHLs. Further work is required to determine prognostic factors in ovarian NHL.
由于原发性卵巢非霍奇金淋巴瘤（NHL）患者的预后存在争议，我们回顾性分析了1974年至1993年在德克萨斯大学MD安德森癌症中心就诊的成年患者的情况。纳入标准为至少一侧卵巢有病理累及，且采用了包含多柔比星用于中级组织学类型的联合化疗。我们确定了15例患者，占同期我院所有未治疗NHL患者的0.5%，未治疗卵巢肿瘤患者的1.5%。1例患者拒绝治疗，剩余14例可评估疗效。9例为中级，5例为高级，无低级NHL患者。4例患者仅一侧卵巢受累，10例双侧受累，其中7例有其他部位受累，包括2例有膈上淋巴结受累。4例患者美国东部肿瘤协作组（ECOG）体能状态为1级，10例为4级。国际预后指数（IPI）评分良好（0或1分）和不良（>1分）的患者分别有5例和9例。所有患者的完全缓解率为64%，所有可评估患者的5年生存率和无进展生存期（FFS）分别为57%和46%。我们得出结论，接受适当化疗的卵巢NHL患者的完全缓解率和FFS似乎与其他淋巴结NHL患者相似。需要进一步研究以确定卵巢NHL的预后因素。
